Mapping radiation dose in real time: a smarter way to treat prostate cancer?

NCT ID NCT07096999

Recruiting now Knowledge-focused Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This study investigates whether SPECT/CT scans can accurately measure the radiation dose delivered to tumors and healthy organs during 177Lu-PSMA-617 (Pluvicto) therapy for metastatic castration-resistant prostate cancer. Researchers will enroll 60 men scheduled for this treatment and compare imaging-based dose estimates with actual treatment response and side effects. The goal is to develop models that could one day help personalize dosing for better outcomes and fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 177Lu-PSMA-617 (Pluvicto) radioligand therapy
What this could lead to: If successful, this could help doctors personalize the dose of 177Lu-PSMA-617 therapy to maximize tumor damage while minimizing harm to healthy organs.
What could go wrong: This is an observational imaging study, not a treatment trial. It will not directly test whether adjusting doses improves outcomes, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CARCINOMA

Contacts and locations

Locations

University of Michigan Comprehensive Cancer Center
RECRUITING

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.